- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02392221
Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). (Inspired)
Study Overview
Status
Conditions
Detailed Description
Crohn's disease (CD) and ulcerative colitis (UC) are chronic Inflammatory Bowel Disease (IBD) and may affect all segments of the digestive tract. These are diseases of multifactorial origin in which environmental and genetic factors are predominant.The EPIMAD registry, the world's largest epidemiological register for IBD, identifying all incident cases in the four departments of the North West of France showed between 1988 and 2007, an increase in the annual incidence of MC 71 % (6.5 / 105 (1988-1990) 11.1 / 105 (2006-2007) p <0.0001) in the age group 10-19 years. At the same time, the annual incidence of UC decreased 4.3 / 3.5 105 inhabitants / 105 inhabitants (20%), with phenotypic presentation remained stable. The increase in the incidence of CD will contribute to increase its weight in the health system, particularly in the pediatric CD frequently associated with an aggressive phenotype causing specific complications such as malnutrition, pubertal delay or thrive. These complications have a important impact on the quality of life with a long-term risk of functional disability. They may be associated with increased mortality. Immunosuppressants (azathioprine, methotrexate) have been used in pediatric forms only from the 90s and anti-TNF antibodies (infliximab and adalimumab), until the 2000s. These new therapeutic classes have profoundly changed the management of pediatric IBD. Although there is little data on the impact of these new treatments, early introduction of immunosuppressive and anti-TNFs seems to influence the natural history of IBD diagnosed in pediatric age. Anti-TNFs appear to be associated with more frequent and deeper remission. With the advent of these new treatment, new therapeutic targets such as endoscopic mucosal healing and more recently the deep remission combining clinical remission, biological and endoscopic, appears. However there is no data in the general population assessing the impact of new treatments and new therapeutic strategies in the pediatric population. Potential risks associated with the increasing use and early use of biological treatments in this particular population remain to be determined in the general population.
The main hypothesis of this study is that changes in therapeutic strategies in IBD diagnosed before 17 yeras old could influence the cumulative incidence of surgical resection and complications specific to this population as failure to thrive and delayed puberty, insertion socio-professional, the extension of the disease, hospitalization rates, and the rate of cancer.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59000
- CHRU Lille
-
Rouen, France, 7700
- CHU Rouen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients in the pediatric cohort EPIMAD registry with a diagnosis of CD or UC or probable between 1988 and 2011.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence of surgical resection in CD and colectomy in pediatric UC
Time Frame: end of follow up
|
Cumulative incidence of surgical resection in CD and colectomy in pediatric ulcerative colitis, depending on the date of diagnosis and the possibility of using immunosuppressants and / or anti-TNFs.
|
end of follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease extension according to Montreal classification
Time Frame: end of follow up
|
Phenotype of MICI maximum monitoring (Montreal classification), according to the date of diagnosis
|
end of follow up
|
Treatment during the follow up
Time Frame: end of follow up
|
treatment
|
end of follow up
|
information about occurrence of postoperative complications
Time Frame: end of follow up
|
Presence, date and type of occurrence of postoperative complications (Dindo classification).
|
end of follow up
|
Weight and size
Time Frame: end of follow up
|
Weight and size at diagnosis, at the first intestinal resection and at the end of follow up
|
end of follow up
|
Hospitalisations
Time Frame: end of follow up
|
number, duration, date
|
end of follow up
|
Studies category Socio-Professional
Time Frame: end of follow up
|
Studies category Socio-Professional (CSP) and occupation
|
end of follow up
|
Age of puberty
Time Frame: end of follow up
|
Age of puberty
|
end of follow up
|
Death
Time Frame: end of follow up
|
Death and if so; due date and
|
end of follow up
|
Complications
Time Frame: end of follow up
|
Serious infectious complications and cancer
|
end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD
Time Frame: end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD according comparison of groups of patients
|
end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD
Time Frame: end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD according the period of diagnosis
|
end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD
Time Frame: end of follow up
|
cost-effectiveness evalutation of different management strategies of IBD according Markov model of disease natural history
|
end of follow up
|
Variation of cost-effectiveness ratio of IBD treatment strategies
Time Frame: at 5 years
|
Variation of cost-effectiveness ratio of IBD treatment strategies.
Efficacy will be measured with number of avoided surgeries.
|
at 5 years
|
Variation of cost-effectiveness ratio of IBD treatment strategies
Time Frame: at 15 years
|
Variation of cost-effectiveness ratio of IBD treatment strategies.
Efficacy will be measured with number of avoided surgeries.
|
at 15 years
|
Variation of cost-utility ratio of IBD treatment strategies
Time Frame: at 15 years
|
Variation of cost-utility ratio of IBD treatment strategies.
Efficacy will be measured with number of avoided surgeries.
|
at 15 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Mathurin Fumery, Doctor, CHU Amiens France
- Study Director: Jean-Louis Dupas, professor, CHU Amiens France
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2013_843_0022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Inflammatory Bowel Disease
-
McMaster UniversityCompletedPediatric Ulcerative Colitis | Pediatric Crohns Disease | Pediatric Inflammatory Bowel DiseasesCanada
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Klinikum Westbrandenburg GmbHUnknown
-
McMaster Children's HospitalSt. Justine's HospitalCompletedInflammatory Bowel Diseases | Crohn Disease | Colitis | Pediatric Crohns DiseaseCanada
-
Laura MacknerChildren's Hospital Medical Center, CincinnatiRecruitingInflammatory Bowel Diseases | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited States
-
Cardiff and Vale University Health BoardRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited Kingdom
-
Hôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France; NestléUnknownCrohn's Disease | PediatricFrance
-
Hospices Civils de LyonNot yet recruitingCrohn Disease | Pediatric Crohns DiseaseFrance
-
University of North Carolina, Chapel HillUniversity of Amsterdam; Crohn's and Colitis FoundationRecruitingCrohn Disease | Pediatric Crohns DiseaseNetherlands, United States, Canada, Israel
-
Children's Hospital Los AngelesCompleted